{"id":"NCT01489189","sponsor":"Jaeb Center for Health Research","briefTitle":"Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy","officialTitle":"Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2015-01","completion":"2018-02-05","firstPosted":"2011-12-09","resultsPosted":"2016-06-01","lastUpdate":"2021-10-29"},"enrollment":305,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Proliferative Diabetic Retinopathy"],"interventions":[{"type":"OTHER","name":"Prompt Panretinal Photocoagulation","otherNames":[]},{"type":"DRUG","name":"0.5-mg Ranibizumab","otherNames":[]},{"type":"OTHER","name":"Deferred panretinal photocoagulation","otherNames":[]}],"arms":[{"label":"Anti-VEGF+Deferred PRP","type":"EXPERIMENTAL"},{"label":"Prompt PRP","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the protocol is to determine if visual acuity outcomes at 2 years in eyes with proliferative diabetic retinopathy (PDR) that receive anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard prompt PRP therapy.\n\nSecondary objectives include:\n\n* Comparing other visual function outcomes (including Humphrey visual field testing and study participant self-reports of visual function) in eyes receiving anti-VEGF with deferred PRP with those in eyes receiving prompt PRP.\n* Determining percent of eyes not requiring PRP when anti-VEGF is given in the absence of prompt PRP.\n* Comparing safety outcomes between treatment groups.\n* Comparing associated treatment and follow-up exam costs between treatment groups.","primaryOutcome":{"measure":"Mean Change in Visual Acuity From Baseline","timeFrame":"2-years","effectByArm":[{"arm":"Anti-VEGF+Deferred PRP","deltaMin":2.8,"sd":null},{"arm":"Prompt PRP","deltaMin":0.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":48,"countries":["United States"]},"refs":{"pmids":["26583372","27101313","27523491","28161147","28492920","28492921","29135802","29980333","30043039","30096354","30807516","31984762","31999300","31647496","26565927","36774994","34673898"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":89},"commonTop":["Vitreous haemorrhage","Vitreous floaters","Vision blurred","Eye pain","Visual acuity reduced"]}}